Impairment of neuronal mitochondrial function by l-DOPA in the absence of oxygen-dependent auto-oxidation and oxidative cell damage

L-3,4-Dihydroxyphenylalanin (l-DOPA or levodopa) is currently the most used drug to treat symptoms of Parkinson’s disease (PD). After crossing the blood–brain barrier, it is enzymatically converted to dopamine by neuronal cells and restores depleted endogenous neurotransmitter levels. l-DOPA is pron...

Descripción completa

Detalles Bibliográficos
Autores principales: Hörmann, Philipp, Delcambre, Sylvie, Hanke, Jasmin, Geffers, Robert, Leist, Marcel, Hiller, Karsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257685/
https://www.ncbi.nlm.nih.gov/pubmed/34226525
http://dx.doi.org/10.1038/s41420-021-00547-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257685/
https://www.ncbi.nlm.nih.gov/pubmed/34226525
http://dx.doi.org/10.1038/s41420-021-00547-4

Ejemplares similares